Recent IPOs & Growth Stocks: Uncovering the Future Giants of the Stock Market

Tag: Funanc1al Insider Series

Cartoon gorilla investor in a business suit on top of a crowned apartment building labeled AppFolio, surrounded by flying dollar bills and a giant ‘BUY’ sign.

Appfolio: Ape Folly or Invest with Director?

A $4.8M insider buy, soaring revenue, and a fresh $300M buyback make AppFolio a head-turner. But with high valuations and stiff competition, is this a property play or a portfolio prank?

Read entire article

Tags: APPF Stock, Appfolio Stock, DIrector Buying, Director Insider Buying, Funanc1al Edge, Funanc1al for Investors, Funanc1al Insider Series, Funanc1al Investing, Funanc1alEdge, Funanc1alInvesting, Funanc1alStocks, Growth Investing, insider buying, Insider Buys, Insider Purchases, insider trading, InsiderActivity, InsiderBuying, InsiderBuys, InsiderPurchases, InsiderTrading, Real Estate Growth Investing
Cartoon of a CRISPR enzyme snipping DNA while hedge fund managers (ARKK & Baker Bros) cheer, and an insider waves a giant $1M buy ticket.

Intellia Therapeutics Update: Insider Buys, Institutional Muscle & Phase 3 Momentum

Intellia Therapeutics (NTLA) is up 20%, insiders are buying, ARKK and Baker Bros are holding or adding, and Phase 3 trials are moving faster than expected. Here’s why CRISPR medicine may be ready for prime time — or another plot twist.

Read entire article

Tags: ARKK, ARKK Fund, ATTR Amyloidosis, Baker Bros, Biotech, Biotech Investing, Biotech Investments, Biotech Partnerships, Biotech Stocks, Biotechnology, Biotechnology Innovation, Cathie Wood, Cathie Wood Stocks, CRISPR, CRISPR Gene Editing, Fun biotech, Funanc1al, Funanc1al Contrarian Plays, Funanc1al Insider Series, Funanc1al Stocks to Watch, FUNanc1alEdge, funanc1alstocks, gene editing, HAE, High Risk High Reward, Intellia, Intellia Therapeutics, investing humor, NTLA, Phase 3 biotech, Regeneron, Stocks & Fun